Susan Gail Kreissman
Professor of Pediatrics
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). Results of this protocol have been published " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" and established the new standard of using unpurged PBSC to support autologous transplant in high risk neuroblastoma. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.
Current Research Interests
Clinical Trials for Pediatric Cancer
Current Appointments & Affiliations
- Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2009
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2000
Contact Information
- 393 Hanes House, Durham, NC 27710
- Box 102382 DUMC, Durham, NC 27710
-
kreis001@mc.duke.edu
(919) 684-3401
- Background
-
Education, Training, & Certifications
- Research Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital Boston 1989 - 1991
- Clinical Fellow, Pediatric Hematology/Oncology, Pediatrics, Children's Hospital Boston 1988 - 1989
- Resident, Pediatrics, Children's Hospital Boston 1986 - 1988
- Intern, Pediatrics, Children's Hospital Boston 1985 - 1986
- M.D., Icahn School of Medicine at Mount Sinai 1985
-
Duke Appointment History
- Associate Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2006 - 2009
- Associate Clinical Professor of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2001 - 2006
- Instructor, Temporary in the Department of Pediatrics, Pediatrics, Hematology-Oncology, Pediatrics 2000 - 2001
- Recognition
-
Awards & Honors
- Research
-
Selected Grants
- COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc. awarded by Children's Hospital of Philadelphia 2013 - 2021
- COG WORK ORDER: (PROJECT: EVERYCHILD (APEC14B1) PCR - COG FOUNDATION awarded by Children's Hospital of Philadelphia 2015 - 2021
- ALTE15N2 STUDY awarded by Children's Hospital of Philadelphia 2017 - 2020
- COG WORK ORDER: (PROJECT: PEDIATRIC MATCH (APEC1621SC) PCR - COG FOUNDATION awarded by Children's Hospital of Philadelphia 2017 - 2020
- COG Work Order: AALL1131: Ph III Clofarabine in High Risk B ALL awarded by Children's Hospital of Philadelphia 2015 - 2020
- COG WORK ORDER: BIQSFP AALL1131 awarded by Children's Hospital of Philadelphia 2016 - 2019
- A Phase I trial of pomalidomide for children with recurrent, progressive or refractory CNS tumors awarded by St. Jude Children's Research Hospital 2015 - 2017
- Pediatric Brain Tumor Consortium awarded by St. Jude Children's Research Hospital 2014 - 2017
- Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma awarded by Alex's Lemonade Stand 2013 - 2015
- COG Work Order AALL07P1--Millennium Pharmaceuticals, Inc. awarded by Children's Hospital of Philadelphia 2013 - 2015
-
External Relationships
- AExtrak, LLC
- Champions Oncology
- Johnson & Johnson
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Liu, Kevin X., Arlene Naranjo, Fan F. Zhang, Steven G. DuBois, Steve E. Braunstein, Stephan D. Voss, Geetika Khanna, et al. “Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.” J Clin Oncol 38, no. 24 (August 20, 2020): 2741–52. https://doi.org/10.1200/JCO.19.03316.Full Text Link to Item
-
Rashid, Tooba, Rochelle Bagatell, Bruce Pawel, Rex C. Bentley, Susan G. Kreissman, and Michael D. Deel. “More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma.” J Pediatr Hematol Oncol, August 4, 2020. https://doi.org/10.1097/MPH.0000000000001901.Full Text Link to Item
-
Park, Julie R., Susan G. Kreissman, Wendy B. London, Arlene Naranjo, Susan Lerner Cohn, Michael D. Hogarty, Sheena C. Tenney, et al. “Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.” Jama 322, no. 8 (August 27, 2019): 746–55. https://doi.org/10.1001/jama.2019.11642.Full Text Link to Item
-
Braunstein, Steve E., Wendy B. London, Susan G. Kreissman, Judith G. Villablanca, Andrew M. Davidoff, Kenneth DeSantes, Robert P. Castleberry, et al. “Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.” Pediatr Blood Cancer 66, no. 7 (July 2019): e27736. https://doi.org/10.1002/pbc.27736.Full Text Link to Item
-
Fangusaro, Jason, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Lindeman, Anuradha Banerjee, et al. “Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.” Lancet Oncol 20, no. 7 (July 2019): 1011–22. https://doi.org/10.1016/S1470-2045(19)30277-3.Full Text Link to Item
-
Pinto, Navin, Arlene Naranjo, Emily Hibbitts, Susan G. Kreissman, M Meaghan Granger, Meredith S. Irwin, Rochelle Bagatell, et al. “Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).” Eur J Cancer 112 (May 2019): 66–79. https://doi.org/10.1016/j.ejca.2019.02.003.Full Text Link to Item
-
Ezekian, Brian, Michael S. Mulvihill, Paul M. Schroder, Brian F. Gilmore, Harold J. Leraas, Brian C. Gulack, Sarah Jane Commander, et al. “Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma.” Pediatr Transplant 22, no. 8 (December 2018): e13305. https://doi.org/10.1111/petr.13305.Full Text Link to Item
-
Depuydt, Pauline, Valentina Boeva, Toby D. Hocking, Robrecht Cannoodt, Inge M. Ambros, Peter F. Ambros, Shahab Asgharzadeh, et al. “Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.” J Natl Cancer Inst 110, no. 10 (October 1, 2018): 1084–93. https://doi.org/10.1093/jnci/djy022.Full Text Link to Item
-
Yanik, Gregory A., Marguerite T. Parisi, Arlene Naranjo, Helen Nadel, Michael J. Gelfand, Julie R. Park, Ruth L. Ladenstein, et al. “Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.” J Nucl Med 59, no. 3 (March 2018): 502–8. https://doi.org/10.2967/jnumed.117.195883.Full Text Link to Item
-
Ladenstein, Ruth, Bieke Lambert, Ulrike Pötschger, Maria-Rita Castellani, Valerie Lewington, Zvi Bar-Sever, Aurore Oudoux, et al. “Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.” Eur J Nucl Med Mol Imaging 45, no. 2 (February 2018): 292–305. https://doi.org/10.1007/s00259-017-3829-7.Full Text Link to Item
-
DuBois, Steven G., Rajen Mody, Arlene Naranjo, Collin Van Ryn, Douglas Russ, Derek Oldridge, Susan Kreissman, et al. “MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.” Pediatr Blood Cancer 64, no. 11 (November 2017). https://doi.org/10.1002/pbc.26545.Full Text Link to Item
-
La Quaglia, Michael P., Daphne Haas-Kogan, Julie Park, Susan G. Kreissman, Daniel von Allmen, Andrew Davidoff, Wendy B. London, and Geetika Khanna. “Reply to J. Stenman et al.” J Clin Oncol 35, no. 17 (June 10, 2017): 1966–67. https://doi.org/10.1200/JCO.2017.72.2777.Full Text Link to Item
-
Allmen, Daniel von, Andrew M. Davidoff, Wendy B. London, Collin Van Ryn, Daphne A. Haas-Kogan, Susan G. Kreissman, Geetika Khanna, Nancy Rosen, Julie R. Park, and Michael P. La Quaglia. “Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.” J Clin Oncol 35, no. 2 (January 10, 2017): 208–16. https://doi.org/10.1200/JCO.2016.67.2642.Full Text Link to Item
-
Temple, William, Lori Mendelsohn, Grace E. Kim, Erin Nekritz, W Clay Gustafson, Lawrence Lin, Kathy Giacomini, et al. “Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.” Eur J Nucl Med Mol Imaging 43, no. 7 (July 2016): 1396. https://doi.org/10.1007/s00259-016-3381-x.Full Text Link to Item
-
Temple, William, Lori Mendelsohn, Grace E. Kim, Erin Nekritz, W Clay Gustafson, Lawrence Lin, Kathy Giacomini, et al. “Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.” Eur J Nucl Med Mol Imaging 43, no. 3 (March 2016): 474–81. https://doi.org/10.1007/s00259-015-3179-2.Full Text Link to Item
-
Englum, Brian R., Kristy L. Rialon, Paul J. Speicher, Brian Gulack, Timothy A. Driscoll, Susan G. Kreissman, and Henry E. Rice. “Value of surgical resection in children with high-risk neuroblastoma.” Pediatric Blood & Cancer 62, no. 9 (September 2015): 1529–35. https://doi.org/10.1002/pbc.25504.Full Text
-
Rice, Henry E., Brian R. Englum, Brian C. Gulack, Obinna O. Adibe, Elizabeth T. Tracy, Susan G. Kreissman, and Jonathan C. Routh. “Use of patient registries and administrative datasets for the study of pediatric cancer.” Pediatr Blood Cancer 62, no. 9 (September 2015): 1495–1500. https://doi.org/10.1002/pbc.25506.Full Text Link to Item
-
Bleeker, G., B. L. van Eck-Smit, K. H. Zwinderman, R. Versteeg, M. M. van Noesel, B. L. Kam, G. J. Kaspers, et al. “MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.” European Journal of Nuclear Medicine and Molecular Imaging 42, no. 2 (February 1, 2015): 222–30. https://doi.org/10.1007/s00259-014-2909-1.Full Text
-
Bleeker, Gitta, Berthe L. van Eck-Smit, Koos H. Zwinderman, Rogier Versteeg, Max M. van Noesel, Boen L. Kam, Gertjan J. Kaspers, et al. “MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.” European Journal of Nuclear Medicine and Molecular Imaging 42, no. 2 (February 2015): 222–30. https://doi.org/10.1007/s00259-014-2909-1.Full Text
-
Ladenstein, R., A. Boubaker, B. Lambert, M. R. Castellani, Z. Bar-Sever, A. Oudoux, A. Kaminska, S. G. Kreissman, K. K. Matthay, and U. Poetschger. “SIGNIFICANT PROGNOSTIC RESULTS OF THE SIOPEN MIBG SCORING METHOD IN 2 COOPERATIVE INDEPENDENT HIGH RISK NEUROBLASTOMA TRIALS.” Pediatric Blood & Cancer 61 (December 1, 2014): S123–S123.Link to Item
-
Landier, Wendy, Kristin Knight, F Lennie Wong, Jin Lee, Ola Thomas, Heeyoung Kim, Susan G. Kreissman, et al. “Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 6 (February 2014): 527–34. https://doi.org/10.1200/jco.2013.51.2038.Full Text
-
Kreissman, Susan G., Robert C. Seeger, Katherine K. Matthay, Wendy B. London, Richard Sposto, Stephan A. Grupp, Daphne A. Haas-Kogan, et al. “Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.” Lancet Oncol 14, no. 10 (September 2013): 999–1008. https://doi.org/10.1016/S1470-2045(13)70309-7.Full Text Link to Item
-
Yanik, Gregory A., Marguerite T. Parisi, Barry L. Shulkin, Arlene Naranjo, Susan G. Kreissman, Wendy B. London, Judith G. Villablanca, et al. “Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.” J Nucl Med 54, no. 4 (April 2013): 541–48. https://doi.org/10.2967/jnumed.112.112334.Full Text Link to Item
-
Bleeker, Gitta, Huib N. Caron, Berthe L. F. van Eck-Smit, Rogier Versteeg, Susan G. Kreissman, Gregory Yanik, and Godelieve A. Tytgat. “DISTINCT METASTATIC PATTERNS IN NEUROBLASTOMA ARE CORRELATED WITH MYCN AMPLIFICATION.” Pediatric Blood & Cancer 59, no. 6 (December 1, 2012): 1057–58.Link to Item
-
Asgharzadeh, Shahab, Jill A. Salo, Lingyun Ji, André Oberthuer, Matthias Fischer, Frank Berthold, Michael Hadjidaniel, et al. “Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.” J Clin Oncol 30, no. 28 (October 1, 2012): 3525–32. https://doi.org/10.1200/JCO.2011.40.9169.Full Text Link to Item
-
Shah, Nirmish R., Daniel B. Landi, Susan G. Kreissman, Evan Kulbachi, and Cassandra Moran. “Presentation and outcomes for children with bone marrow necrosis and acute lymphoblastic leukemia: a literature review.” J Pediatr Hematol Oncol 33, no. 7 (October 2011): e316–19. https://doi.org/10.1097/MPH.0b013e318223fe9b.Full Text Link to Item
-
Naranjo, Arlene, Marguerite T. Parisi, Barry L. Shulkin, Wendy B. London, Katherine K. Matthay, Susan G. Kreissman, and Gregory A. Yanik. “Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.” Pediatric Blood & Cancer 56, no. 7 (July 2011): 1041–45. https://doi.org/10.1002/pbc.22991.Full Text
-
Landier, W., K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim, S. G. Kreissman, et al. “Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales—A report from the Children's Oncology Group (COG).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 9515–9515. https://doi.org/10.1200/jco.2011.29.15_suppl.9515.Full Text
-
Landier, W., K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim, S. G. Kreissman, et al. “Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 9515.Link to Item
-
Yu, Alice L., Andrew L. Gilman, M Fevzi Ozkaynak, Wendy B. London, Susan G. Kreissman, Helen X. Chen, Malcolm Smith, et al. “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.” N Engl J Med 363, no. 14 (September 30, 2010): 1324–34. https://doi.org/10.1056/NEJMoa0911123.Full Text Link to Item
-
Yanik, G. A., M. T. Parisi, A. Naranjo, K. K. Matthay, W. B. London, P. W. McGrady, S. G. Kreissman, and B. L. Shulkin. “MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 9516–9516. https://doi.org/10.1200/jco.2010.28.15_suppl.9516.Full Text
-
Bensimhon, Pamela, Judith G. Villablanca, Leonard S. Sender, Katherine K. Matthay, Julie R. Park, Robert Seeger, Wendy B. London, John Stephen F. Yap, and Susan G. Kreissman. “Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.” Pediatr Blood Cancer 54, no. 4 (April 2010): 596–602. https://doi.org/10.1002/pbc.22344.Full Text Link to Item
-
Kreissman, S. G., J. G. Villablanca, R. C. Seeger, S. A. Grupp, W. B. London, J. M. Maris, J. R. Park, S. L. Cohn, K. K. Matthay, and C. P. Reynolds. “A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 10011.Link to Item
-
Kreissman, S. G., J. G. Villablanca, R. C. Seeger, S. A. Grupp, W. B. London, J. M. Maris, J. R. Park, S. L. Cohn, K. K. Matthay, and C. P. Reynolds. “A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 10011–10011. https://doi.org/10.1200/jco.2008.26.15_suppl.10011.Full Text
-
Cornetta, K., J. Croop, E. Dropcho, R. Abonour, M. W. Kieran, S. Kreissman, L. Reeves, L. C. Erickson, and D. A. Williams. “A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.” Cancer Gene Ther 13, no. 9 (September 2006): 886–95. https://doi.org/10.1038/sj.cgt.7700963.Full Text Link to Item
-
Pradhan, Kamnesh R., Cynthia S. Johnson, Terry A. Vik, Leonard S. Sender, and Susan G. Kreissman. “A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.” Pediatr Blood Cancer 46, no. 7 (June 2006): 793–802. https://doi.org/10.1002/pbc.20594.Full Text Link to Item
-
Cairo, Mitchell S., Virginia Davenport, Olga Bessmertny, Stanton C. Goldman, Stacy L. Berg, Susan G. Kreissman, Joseph Laver, et al. “Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.” Br J Haematol 128, no. 1 (January 2005): 49–58. https://doi.org/10.1111/j.1365-2141.2004.05281.x.Full Text Link to Item
-
Hawkins, Douglas S., Judy Felgenhauer, Julie Park, Susan Kreissman, Blythe Thomson, James Douglas, Scott D. Rowley, Ted Gooley, Jean E. Sanders, and Thomas W. Pendergrass. “Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.” Cancer 95, no. 6 (September 15, 2002): 1354–65. https://doi.org/10.1002/cncr.10801.Full Text Link to Item
-
Croop, J. M., R. Cooper, C. Fernandez, V. Graves, S. Kreissman, H. Hanenberg, F. O. Smith, and D. A. Williams. “Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia.” Blood 98, no. 10 (November 15, 2001): 2917–21. https://doi.org/10.1182/blood.v98.10.2917.Full Text Link to Item
-
Goldman, S. C., J. S. Holcenberg, J. Z. Finklestein, R. Hutchinson, S. Kreissman, F. L. Johnson, C. Tou, E. Harvey, E. Morris, and M. S. Cairo. “A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.” Blood 97, no. 10 (May 15, 2001): 2998–3003. https://doi.org/10.1182/blood.v97.10.2998.Full Text Link to Item
-
Croop, J. M., R. Cooper, R. Seshadri, C. Fernandez, V. Graves, S. Kreissman, F. O. Smith, K. Cornetta, D. A. Williams, and R. Abonour. “Large-scale mobilization and isolation of CD34+ cells from normal donors.” Bone Marrow Transplant 26, no. 12 (December 2000): 1271–79. https://doi.org/10.1038/sj.bmt.1702720.Full Text Link to Item
-
Wingard, J. R., M. H. White, E. Anaissie, J. Raffalli, J. Goodman, A. Arrieta, E. Albano, et al. “A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia.” Clinical Infectious Diseases 31, no. 5 (2000): 1155–63. https://doi.org/10.1086/317451.Full Text
-
Asselin, B. L., S. Kreissman, D. J. Coppola, S. D. Bernal, P. R. Leavitt, R. D. Gelber, S. E. Sallan, and H. J. Cohen. “Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.” J Pediatr Hematol Oncol 21, no. 1 (January 1999): 6–12. https://doi.org/10.1097/00043426-199901000-00003.Full Text Link to Item
-
McCarthy, L., F. O. Smith, D. Emanuel, A. Orazi, C. Danielson, C. Thompson, C. Thomas, and S. Kreissman. “Platelet depletion during pediatric peripheral blood progenitor cell (PBPC) harvesting.” Transfusion Science 19, no. 1 (July 8, 1998). https://doi.org/10.1016/S0955-3886(98)00016-2.Full Text
-
Dagher, R., S. Kreissman, K. A. Robertson, A. Provisor, J. Bergstein, K. Burke, J. H. Rodman, D. Emanuel, and F. O. Smith. “High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor.” Journal of Pediatric Hematology/Oncology 20, no. 4 (July 1998): 357–60. https://doi.org/10.1097/00043426-199807000-00016.Full Text
-
Goldman, S., V. Davenport, G. Reaman, J. Laver, S. Kreissman, B. Blazar, S. Berg, J. Kaye, F. Patterson, and M. S. Cairo. “Combination of rhIL-11 + G-CSF enhances platelet (PLT) and myeloid recovery following ifosfamide, carboplatin, and etoposdde (ICE) chemotherapy in children with solid tumors (ST): RML-11 is well tolerated at double the adult recommended dose.” Experimental Hematology 25, no. 8 (December 1, 1997): 786.
-
Kreissman, S. G., W. Rackoff, M. Lee, and P. P. Breitfeld. “High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.” Journal of Pediatric Hematology/Oncology 19, no. 4 (July 1997): 309–12. https://doi.org/10.1097/00043426-199707000-00008.Full Text
-
Hinds, P. S., L. K. Birenbaum, L. Clarke-Steffen, A. Quargnenti, S. Kreissman, A. Kazak, W. Meyer, R. Mulhern, C. Pratt, and J. Wilimas. “Coming to terms: parents' response to a first cancer recurrence in their child.” Nurs Res 45, no. 3 (May 1996): 148–53. https://doi.org/10.1097/00006199-199605000-00005.Full Text Link to Item
-
Rackoff, W. R., R. Gonin, C. Robinson, S. G. Kreissman, and P. B. Breitfeld. “Predicting the risk of bacteremia in childen with fever and neutropenia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 14, no. 3 (March 1996): 919–24. https://doi.org/10.1200/jco.1996.14.3.919.Full Text
-
Kreissman, S. G. “Molecular genetics: toward an understanding of childhood cancer.” Semin Pediatr Surg 2, no. 1 (February 1993): 2–10.Link to Item
-
MACKLIS, R. M., D. C. WEST, R. C. SHAMBERGER, H. P. KOZAKEWICH, S. G. KREISSMAN, and H. E. GRIER. “LOCAL-CONTROL IN STAGE-III NEUROBLASTOMA PATIENTS OVER ONE-YEAR OF AGE - THE JOINT CENTER CHILDRENS-HOSPITAL DANA-FARBER-CANCER-INSTITUTE EXPERIENCE.” International Journal of Radiation Oncology Biology Physics 27 (January 1, 1993): 131–32.Link to Item
-
West, D. C., R. C. Shamberger, R. M. Macklis, H. P. Kozakewich, A. S. Wayne, S. G. Kreissman, B. R. Korf, B. Lavally, and H. E. Grier. “Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 11, no. 1 (January 1993): 84–90. https://doi.org/10.1200/jco.1993.11.1.84.Full Text
-
Kreissman, S. G., R. D. Gelber, H. J. Cohen, L. A. Clavell, P. Leavitt, and S. E. Sallan. “Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia.” Cancer 70, no. 8 (October 15, 1992): 2208–13. https://doi.org/10.1002/1097-0142(19921015)70:8<2208::aid-cncr2820700832>3.0.co;2-p.Full Text Link to Item
-
Mathey-Prevot, B., N. C. Andrews, H. S. Murphy, S. G. Kreissman, and D. G. Nathan. “Positive and negative elements regulate human interleukin 3 expression.” Proc Natl Acad Sci U S A 87, no. 13 (July 1990): 5046–50. https://doi.org/10.1073/pnas.87.13.5046.Full Text Link to Item
-
ANDREWS, N. C., B. MATHEYPREVOT, S. G. KREISSMAN, and D. G. NATHAN. “NUCLEAR FACTOR BINDING-SITES IN THE INTERLEUKIN (IL-3) PROMOTER.” Pediatric Research 27, no. 4 (April 1, 1990): A138–A138.Link to Item
-
Vitek, M. P., S. G. Kreissman, and R. H. Gross. “The isolation of ecdysterone inducible genes by hybridization subtraction chromatography.” Nucleic Acids Res 9, no. 5 (March 11, 1981): 1191–1202. https://doi.org/10.1093/nar/9.5.1191.Full Text Link to Item
-
-
Conference Papers
-
Pinto, Navin R., Emily Hibbitts, Susan G. Kreissman, Meaghan P. Granger, Meredith Irwin, Rochelle Bagatell, Wendy B. London, et al. “Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).” In Journal of Clinical Oncology, 36:10532–10532. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.10532.Full Text
-
Fangusaro, Jason, Arzu Onar-Thomas, Tina Y. Poussaint, Shengjie Wu, Azra H. Ligon, Neal Lindeman, Anu Banerjee, et al. “A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY.” In Neuro Oncology, 19:34–35. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Fangusaro, Jason R., Arzu Onar-Thomas, Tina Young-Poussaint, Shengjie Wu, Azra H. Ligon, Neal Ian Lindeman, Anuradha Banerjee, et al. “A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.” In Journal of Clinical Oncology, 35:10504–10504. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.10504.Full Text
-
Poetschger, U., A. Naranjo, G. Yanik, M. R. Castellani, B. Lambert, V. Lewington, Z. Bar-Server, et al. “The Way Towards an International MIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective.” In Pediatric Blood & Cancer, 63:S39–40. WILEY-BLACKWELL, 2016.Link to Item
-
Park, Julie R., Susan G. Kreissman, Wendy B. London, Arlene Naranjo, Susan Lerner Cohn, Michael D. Hogarty, Sheena Cretella Tenney, et al. “A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.” In Journal of Clinical Oncology, 34:LBA3–LBA3. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.18_suppl.lba3.Full Text
-
DuBois, Steven G., Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker, Marguerite T. Parisi, et al. “Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG).” In Journal of Clinical Oncology, 34:10526–10526. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.10526.Full Text
-
DuBois, Steven G., William Temple, Lori Mendelsohn, Grace E. Kim, Erin Nekritz, Clay Gustafson, Lawrence Lin, et al. “Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Children's Oncology Group.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Yanik, Gregory, Arlene Naranjo, Marguerite T. Parisi, Barry L. Shulkin, Helen Nadel, Michael J. Gelfand, Ruth Ladenstein, et al. “Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma.” In Biology of Blood and Marrow Transplantation, 21:S107–S107. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.131.Full Text
-
Boubaker, A., U. Poetschger, B. Lambert, M. R. Castellani, Z. Bar-Sever, A. Oudoux, A. Kaminska, et al. “Validation of the mIBG SIOPEN Scoring Method in 2 independent High Risk Neuroblastoma Trial Populations.” In European Journal of Nuclear Medicine and Molecular Imaging, 41:S220–S220. SPRINGER, 2014.Link to Item
-
Haas-Kogan, D., J. Douglas, W. B. London, C. J. McCauley Van Ryn, D. von Allmen, A. M. Davidoff, J. G. Villablanca, et al. “Extent of Lymph Node Radiation Coverage in High-Risk Neuroblastoma Does Not Affect Clinical Outcome: A Report From the COG A3973 Study.” In International Journal of Radiation Oncology*Biology*Physics, 90:S114–S114. Elsevier BV, 2014. https://doi.org/10.1016/j.ijrobp.2014.05.539.Full Text
-
Boubaker, Ariane, Ulrike Poetschger, Bieke Lambert, Maria Rita Castellani, Zvi Bar-Sever, Aurore Oudoux, Anna Kaminska, et al. “Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.” In Journal of Clinical Oncology, 32:10029–10029. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.10029.Full Text
-
Yanik, Gregory A., Arlene Naranjo, Marguerite T. Parisi, Barry L. Shulkin, Helen R. Nadel, Michael J. Gelfand, Ruth L. Ladenstein, et al. “Validation of postinduction Curie scores in high-risk neuroblastoma.” In Journal of Clinical Oncology, 32:10031–10031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.10031.Full Text
-
Kreissman, S. G., J. G. Villablanca, L. Diller, W. B. London, J. M. Maris, J. R. Park, C. P. Reynolds, D. von Allmen, S. L. Cohn, and K. K. Matthay. “Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
- PEDS 222C: Overview of Pediatric Hematology-Oncology 2021
- PEDS 427C: Pediatric Hematology/Oncology 2021
- PEDS 222C: Overview of Pediatric Hematology-Oncology 2020
- PEDS 427C: Pediatric Hematology/Oncology 2020
- PEDS 222C: Overview of Pediatric Hematology-Oncology 2019
- PEDS 427C: Pediatric Hematology/Oncology 2019
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.